The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.
Following a CRL issued in August 2023, Mesoblast has resubmitted the BLA for remestemcel-L for pediatric patients with SR-aGVHD.1
“We have worked closely with the agency and thank them for their ongoing guidance, facilitating the potential approval of [remestemcel-L] and addressing the urgent need for a therapy that improves the dismal survival outcome in children with SR-aGVHD,” said Silviu Itescu, MBBS, FRACP, chief executive officer of Mesoblast, in a press release.
The CRL noted that there was insufficient data to support approval. The FDA also required Mesoblast to address ongoing problems regarding chemistry, manufacturing, and controls (CMC) before resubmitting the BLA.2
The company announced a controlled study in high-risk adults to meet the FDA requirements, and in March 2024, the FDA decided that there was sufficient evidence to resubmit the BLA. The new filing also addresses the remaining CMC issues.1
The application of remestemcel-L is supported by the phase 3 GVHD001/002 clinical trial (NCT02336230). A total of 54 pediatric patients with SR-aGVHD were evaluated across 20 centers in the US; 89% of patients had grade C/D disease.
The trial met its primary end point of day 28 overall response (OR) with 70.4% vs 45% (P =.0003). The day 28 OR was considered highly predictive of improved survival through day 100, with 87% vs 47% in patients who did not reach day 28 OR (P =.0001).
A matched control group of pediatric patients from the Mount Sinai Acute GVHD International Consortium (MAGIC) treated with the best available therapy was also used for comparison. Here, remestemcel-L led to a higher day 28 OR, with 70% vs 43%, and higher day 100 survival, with 74% vs 57%. Further, using matched propensity scoring, 67% of high-risk patients receiving remestemcel-L reached a day 28 OR and were alive after 180 days vs 10% of patients in the MAGIC group who received best available therapy.
A 4-year survival study conducted by the Center for International Blood and Marrow Transplant Research also found that survival benefits of remestemcel-L were durable, with 67% survival at 6 months, 63% at 1 year, 51% at 2 years, and 49% at 4 years. These patients had an expected 2-year survival of 25% to 38% with best available therapy.
Iomab-B Leads to More Durable Responses vs alloHCT in AML Treatment
September 24th 2024Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs allogeneic cell transplant in older patients with relapsed/refractory acute myeloid leukemia.
Read More
Pacritinib, Sirolimus, and Tacrolimus Combo Fails to Improve GVHD Outcomes
August 10th 2024A phase 2 study found that a combination of pacritinib, sirolimus, and tacrolimus successfully suppressed pSTAT3 and Th1/Th17 cells, but failed to prevent acute graft-versus-host disease following allogeneic transplant.
Read More